“Doctor, if it were you, which would you choose?” Navigating personal preference questions in anti‐amyloid immunotherapy selection

Dr. Eric Dinnerstein is the director of the UT Tyler Dementia Center and will share his insights with us in his workshop on navigating choices related to the most recent treatments available for slowing Alzheimer’s disease.

In his paper of the same name, he writes “The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head‐to‐head comparative data are absent. When confronted with the question “What would you do if you were me?”, clinical providers must balance evidence‐based medicine with the therapeutic alliance.”

Eric Dinnerstein, MD, is a cognitive neurologist specializing in dementia and early cognitive decline who also practices general neurology, caring for adults with a wide range of neurological conditions. He has led a dementia clinic at MaineHealth near Portland for close to 20 years and served as principal investigator for numerous dementia clinical studies and trials.